Dr. John Cush RheumNow
4 years 7 months ago
ICYMI: How Preventable Is Rheumatoid Arthritis?
https://t.co/epc6BvYKzq https://t.co/2hKIuE66zT
Dr. John Cush RheumNow
4 years 7 months ago
ICYMI: NEJM clinical case -42 yoM w/ red, painful eyes, facial-nerve palsy OS, a large oral ulcer, and petechiae. +ANCA, +PR3. Skin biopsy revealed leukocytoclastic vasculitis with perivascular eosinophils. Dx eosinophilic granulomatosis with polyangiitis https://t.co/zXTQYfPa1t
Dr. John Cush RheumNow
4 years 7 months ago
ICYMI: Physical Therapy is More Cost-Effective than Intraarticular Steroids in Knee OA
https://t.co/My5xa8vEaP https://t.co/lGL57nwJiZ
Dr. John Cush RheumNow
4 years 7 months ago
ICYMI: FDA Approves Skyrizi for Active Psoriatic Arthritis
https://t.co/0HpoZYHK2V https://t.co/pvIC6ECqjF
Dr. John Cush RheumNow
4 years 8 months ago
ICYMI: FREED study (asympt hyperuricemic without gout) showed febuxostat x 24 mos dint alter carotid atherosclerosis, but at 3 years, (Substudy of 1004 pts), showed FEB signif lowered risk of CVA, CV, renal renal events and death (vs PBO) https://t.co/x2pYrOBZVG
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com. This week a trifecta of Gout reports and the last word on the ORAL Surveillance study...
Dr. John Cush RheumNow
4 years 8 months ago
Dr. Ernest Choy will be part of the Rheumatoid Faculty panel Q&A at RheumNow Live this March. Grab the mic & ask a question!
Register Today!
https://t.co/aJYMyKMGMn
#RNL2022 https://t.co/oH4oG797XA
In an editorial in the current edition of the NEJM, Dr. Jasvinder Singh comments on the Oral Surveillance trial (Ytterberg et al.), a 4-year randomized, open-label, noninferiority, postauthorization, safety end-point trial, in high risk active rheumatoid arthritis patients over age 50 years.
For adults aged ≥18 years who received 2 doses of an mRNA COVID-19 vaccine, a third dose increased vaccine effectiveness (prevention of hospitalization) among adults without (82% to 97%) and with immunocompromising conditions (69% to 88%), with near similar efficacy.
Dr. John Cush RheumNow
4 years 8 months ago
Join Dr. Cush at RheumNow Live this March as he presents and discusses Treatment Choices in Refractory RA.
https://t.co/11XNOQOwm0 https://t.co/Ar4QeoRRTz
Dr. John Cush RheumNow
4 years 8 months ago
From 1969 hospitalized COVID Spanish pts (46% F, age 61), 31 pts w/ preexisting RMD -- they did not have more long-term post-COVID sxs (OR 1.46; 0.89–2.4), functional limitation (OR 1.058), anxiety, depression or MSK pain vs non-RMD https://t.co/IYJz5zFoLe
Dr. John Cush RheumNow
4 years 8 months ago
819 rheumatic disease pts surved about Telemedicine (TM), available to most (75%). Satisfaction was 7.3/10 w/ 26% very satisfied. Pts preferred TM for routine visits (73%), test results (65%), med changes (41%); but less so for new Injx meds(19%) https://t.co/W8newba0FV
A randomized trial compared the incremental cost-effectiveness of physical therapy and intra-articular glucocorticoid (IA GC) injection as initial treatment for knee osteoarthritis showed that physical therapy gained more quality-adjusted life-years compared with those receiving glucocorticoid injection.
A study in the Annals of Internal Medicine reports chronic kidney disease (CKD) patients can be safely treated with allopurinol without an increased risk of mortality.
